Nrx pharmaceuticals reports third quarter 2023 financial results and provides business update

Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 completing enrollment of the originally-targeted 70 patients in the phase 2b/3 trial of nrx-101 in treatment resistant bipolar depression; enrollment to continue through november to increase study power; last patient visit expected in january. data expected to be released shortly thereafter opened the investigational new drug application (ind) with food and drug administration (fda) to treat chronic pain with nrx-101.
NRXP Ratings Summary
NRXP Quant Ranking